% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Reinartz:139036,
      author       = {Reinartz, Roman and Wang, Shanshan and Kebir, Sied and
                      Silver, Daniel J and Wieland, Anja and Zheng, Tong and
                      Küpper, Marius and Rauschenbach, Laurèl and Fimmers, Rolf
                      and Shepherd, Timothy M and Trageser, Daniel and Till,
                      Andreas and Schäfer, Niklas and Glas, Martin and Hillmer,
                      Axel M and Cichon, Sven and Smith, Amy A and Pietsch,
                      Torsten and Liu, Ying and Reynolds, Brent A and Yachnis,
                      Anthony and Pincus, David W and Simon, Matthias and
                      Brüstle, Oliver and Steindler, Dennis A and Scheffler,
                      Björn},
      title        = {{F}unctional {S}ubclone {P}rofiling for {P}rediction of
                      {T}reatment-{I}nduced {I}ntratumor {P}opulation {S}hifts and
                      {D}iscovery of {R}ational {D}rug {C}ombinations in {H}uman
                      {G}lioblastoma.},
      journal      = {Clinical cancer research},
      volume       = {23},
      number       = {2},
      issn         = {1078-0432},
      address      = {Philadelphia, Pa. [u.a.]},
      publisher    = {AACR},
      reportid     = {DZNE-2020-05358},
      pages        = {562-574},
      year         = {2017},
      abstract     = {Investigation of clonal heterogeneity may be key to
                      understanding mechanisms of therapeutic failure in human
                      cancer. However, little is known on the consequences of
                      therapeutic intervention on the clonal composition of solid
                      tumors.Here, we used 33 single cell-derived subclones
                      generated from five clinical glioblastoma specimens for
                      exploring intra- and interindividual spectra of drug
                      resistance profiles in vitro In a personalized setting, we
                      explored whether differences in pharmacologic sensitivity
                      among subclones could be employed to predict drug-dependent
                      changes to the clonal composition of tumors.Subclones from
                      individual tumors exhibited a remarkable heterogeneity of
                      drug resistance to a library of potential antiglioblastoma
                      compounds. A more comprehensive intratumoral analysis
                      revealed that stable genetic and phenotypic characteristics
                      of coexisting subclones could be correlated with distinct
                      drug sensitivity profiles. The data obtained from
                      differential drug response analysis could be employed to
                      predict clonal population shifts within the naïve parental
                      tumor in vitro and in orthotopic xenografts. Furthermore,
                      the value of pharmacologic profiles could be shown for
                      establishing rational strategies for individualized
                      secondary lines of treatment.Our data provide a previously
                      unrecognized strategy for revealing functional consequences
                      of intratumor heterogeneity by enabling predictive modeling
                      of treatment-related subclone dynamics in human
                      glioblastoma. Clin Cancer Res; 23(2); 562-74. ©2016 AACR.},
      keywords     = {Animals / Clonal Evolution: genetics / Drug Combinations /
                      Drug Resistance, Neoplasm: genetics / Genetic Heterogeneity
                      / Glioblastoma: drug therapy / Glioblastoma: genetics /
                      Glioblastoma: pathology / Humans / Mice / Xenograft Model
                      Antitumor Assays / Drug Combinations (NLM Chemicals)},
      cin          = {Cell Programming Unit},
      ddc          = {610},
      cid          = {I:(DE-2719)1013013},
      pnm          = {344 - Clinical and Health Care Research (POF3-344)},
      pid          = {G:(DE-HGF)POF3-344},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:27521447},
      pmc          = {pmc:PMC5241221},
      doi          = {10.1158/1078-0432.CCR-15-2089},
      url          = {https://pub.dzne.de/record/139036},
}